Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
2,827 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Dulai PS, Singh S, Patel J, et al. · Hepatology · 2017Meta-Analysis, Systematic Review
- The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
Younossi ZM, Golabi P, Paik JM, et al. · Hepatology · 2023Systematic Review, Meta-Analysis
- Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
Quek J, Chan KE, Wong ZY, et al. · Lancet Gastroenterol Hepatol · 2023Meta-Analysis, Systematic Review
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Younossi ZM, Koenig AB, Abdelatif D, et al. · Hepatology · 2016Meta-Analysis, Review
- The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
Younossi ZM, Golabi P, Price JK, et al. · Clin Gastroenterol Hepatol · 2024Meta-Analysis
- Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Ye Q, Zou B, Yeo YH, et al. · Lancet Gastroenterol Hepatol · 2020Meta-Analysis, Systematic Review
- Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
Loomba R, Sanyal AJ, Kowdley KV, et al. · N Engl J Med · 2023Clinical Trial, Phase II, Multicenter Study
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Armstrong MJ, Gaunt P, Aithal GP, et al. · Lancet · 2016Clinical Trial, Phase II, Multicenter Study
- Nonalcoholic fatty liver disease: a systematic review.
Rinella ME · JAMA · 2015Systematic Review
- Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.
Harrison SA, Taub R, Neff GW, et al. · Nat Med · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis.
Lee EJ, Choi M, Ahn SB, et al. · World J Pediatr · 2024Systematic Review, Meta-Analysis
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Newsome PN, Buchholtz K, Cusi K, et al. · N Engl J Med · 2021Clinical Trial, Phase II, Multicenter Study
- Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
En Li Cho E, Ang CZ, Quek J, et al. · Gut · 2023Meta-Analysis, Systematic Review
- Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
Singh S, Allen AM, Wang Z, et al. · Clin Gastroenterol Hepatol · 2015Comparative Study, Meta-Analysis
- Gut fermentation syndrome: A systematic review of case reports.
Bayoumy AB, Mulder CJJ, Mol JJ, et al. · United European Gastroenterol J · 2021Systematic Review
- Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Bandyopadhyay S, Das S, Samajdar SS, et al. · Diabetes Metab Syndr · 2023Meta-Analysis, Systematic Review
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Le MH, Le DM, Baez TC, et al. · Clin Mol Hepatol · 2024Meta-Analysis, Systematic Review
- Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Taylor RS, Taylor RJ, Bayliss S, et al. · Gastroenterology · 2020Meta-Analysis, Research Support, Non-U.S. Gov't
- The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Younossi ZM, Golabi P, de Avila L, et al. · J Hepatol · 2019Meta-Analysis, Research Support, Non-U.S. Gov't
- Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.
Mantovani A, Petracca G, Beatrice G, et al. · Gut · 2022Meta-Analysis, Research Support, Non-U.S. Gov't
- A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
Wah Kheong C, Nik Mustapha NR, Mahadeva S · Clin Gastroenterol Hepatol · 2017Randomized Controlled Trial
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K, Orsak B, Bril F, et al. · Ann Intern Med · 2016Randomized Controlled Trial
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N, Herring R, Kabler H, et al. · J Hepatol · 2022Clinical Trial, Phase II, Randomized Controlled Trial
- Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
Mantovani A, Petracca G, Beatrice G, et al. · Gut · 2022Meta-Analysis, Research Support, Non-U.S. Gov't
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
Selvaraj EA, Mózes FE, Jayaswal ANA, et al. · J Hepatol · 2021Meta-Analysis, Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.